摘要
目的:探讨大承气汤联合血必净治疗早期重症胰腺炎的临床疗效,及其对TNF-α、IL-6、IL-8的影响。方法:选择吉林大学白求恩第一医院急诊科2012年2月至2014年2月诊治的60例确诊为重症胰腺炎的患者为研究对象,采用随机数字表随机分为2组,每组30例。对照组给予西医常规的治疗方案。治疗组在对照组的基础上加用鼻饲大承气汤及血必净静脉滴注治疗,治疗组入院后即给予大承气汤鼻饲治疗,连续治疗7 d;血必净50 m L,2次/d,静脉滴注治疗,连用10 d。观察2组的临床疗效。同时采用ELISA法检测2组患者血清中治疗前及治疗后TNF-α、IL-6、IL-8含量的变化。结果:经治疗后,治疗组的临床疗效优于对照组,腹痛消失、腹胀消失、上腹压痛消失、恢复进食等时间均较对照组缩短,差异均具有统计学意义(P<0.05);治疗组白细胞恢复正常、血尿淀粉酶恢复时间均较对照组缩短,差异均具有统计学意义(P<0.05)。2组患者血清中治疗后TNF-α、IL-6、IL-8的含量均有所下降,差异均具有统计学意义(P<0.05);而治疗组的下降程度较对照组更为明显,差异均具有统计学意义(P<0.05)。结论:早期使用中药制剂大承气汤及血必净能有效的改善重症胰腺炎患者的临床症状,并能降低患者血清中TNF-α、IL-6、IL-8等细胞因子的含量,值得临床推广应用。
Objective： To investigate the clinical efficacy Dachengqi decoction combined with Xuebijing in treating early severe pancreatitis and its influence on TNF-α,IL-6,IL-8. Methods： Sixty cases of patients in our hospital enrolled during February2012 to 2014 who was diagnosed of severe pancreatitis were randomly divided into two groups,with 30 cases in each. The control group received conventional western medicine treatment and the observation group use plus nasogastric Dachengqi decoction continuously 7 days,and Xuebijing intravenous treatment,50 ml bid infusion,10 days. The clinical efficacy,TNF-α,IL-6,IL-8 content changes of the two groups were observed. Results： After treatment,abdominal pain,bloating disappeared time,abdominal tenderness disappeared time,resumed eating in the observation group were shorter than those of the control group,and the differences were statistically significant（ P 〈 0. 05）. The duration of white blood cells returned to normal,urine amylase recovery duration in the observation group was shorter than that of the control group（ P 〈 0. 05）. Serum TNF-α,IL-6,IL-8 levels in both groups have declined,the differences were statistically significant（ P 〈 0. 05）. Besides,the degree of decline in the observation group was more significant than the control group（ P 〈 0. 05）. Conclusion： Dachengqi decoction and Xuebijing can effectively improve the clinical symptoms of patients with severe pancreatitis,can reduce serum TNF-α,IL-6,IL-8 and other cytokines content. It is worthy of clinical application.
出处
《世界中医药》
CAS
2016年第2期232-235,共4页
World Chinese Medicine
基金
国家自然科学基金项目(编号:81303014)
